Recap AMCP 2024: Our thought leadership in action
By AmerisourceBergen
From delivering educational sessions on the evolution of the AMCP format for formulary submissions and the role of pre-approval dossiers in a successful product launch to award-winning research, Cencora was a proud supporter of this year's conference.
Explore some of our expert contributions and related content that showcased our commitment to helping our biopharma partners accelerate product success.
Award-winning research
- Changes in US payer biosimilar coverage policies of granulocyte colony stimulating factor products
- Early implementation of PIE for specific drug categories
- Mind the “pre-approval” gap: Payer pre-approval information needs and how manufacturers can better meet them
- Sourcing value: understanding payer perceptions of value assessment information for formulary decision-making
- US payer perceptions on formulary evaluation and management of cell and gene therapies
- Beyond value assessment reports: a review of payer perspectives on ICER’s initiatives and tools
FormularyDecisions®
Innovation and Impact Award
In the ever-evolving landscape of healthcare, where decisions shape outcomes and information is paramount, the reliance on digital channels for accessing crucial product-related data has become increasingly critical.
The Innovation and Impact Award serves as a beacon of recognition for those who have demonstrated exceptional support for healthcare decision makers needs in formulary decision making. It is awarded annually to distinguished recipients in two distinct categories: mid-to-large biopharma and emerging biopharma.
Congratulations to SpringWorks Therapeutics (Emerging biopharma category) and AbbVie Inc (Mid-to-large biopharma category).
The Innovation and Impact Award serves as a beacon of recognition for those who have demonstrated exceptional support for healthcare decision makers needs in formulary decision making. It is awarded annually to distinguished recipients in two distinct categories: mid-to-large biopharma and emerging biopharma.
Congratulations to SpringWorks Therapeutics (Emerging biopharma category) and AbbVie Inc (Mid-to-large biopharma category).
.jpg?h=320&iar=0&w=540&useCustomFunctions=1¢erCrop=1&hash=DDA1D7BEE906940394C769FA6454A08B)